Date: November 3, 2022
Time: 5:30 - 8:30 pm MST
Location: The Camby Hotel, 2401 E Camelback Rd, Phoenix, AZ 85016
SNMMI has applied for 2 hours of CE Credit for this in-person event.
Please note that seating is limited and registration will be available on a first-come, first-served basis.
Dinner is Served
Several new radiopharmaceuticals are now being used in both large academic and small practice settings to stage and identify local and metastatic prostate cancer, including the recently approved Ga-68 PSMA-11 and 18F-DCFPyL. In addition, the FDA in March approved Lu 177 vipivotide tetraxetan to treat PSMA-positive metastatic castration-resistant prostate cancer. Given these new advancements in diagnosis and treatment, how does one navigate the changing landscape to provide the best outcomes for the patient?
6:30 - 6:35 pm
Welcome and Introductions
Phillip Koo, MD, Division Chief, Diagnostic Imaging, Banner MD Anderson Cancer Center
6:35 - 7:00 pm
Nuclear Medicine Perspective
Meera Raghavan, MD, Radiologist, Banner MD Anderson Cancer Center
7:00 - 7:25 pm
Mmeje Chinedu, MD, Surgical Oncologist, Banner MD Anderson Cancer Center
7:25 - 7:50 pm
Isaac Bowman, MD, Hematologist/Oncologist, Banner MD Anderson Cancer Center
7:50 - 8:05 pm
8:05 - 8:30 pm
Q&A and Panel Discussion
Phillip Koo, MD (moderator); Meera Raghavan, MD; Mmeje Chinedu, MD; Isaac Bowman, MD; and Melanie Pietryka, BA, CNMT, PET, Lead Nuclear Medicine Technologist, Banner MD Anderson Cancer Center
Please note: SNMMI is committed to ensuring that appropriate and necessary health and safety protocols will be in place for this event. We will follow all Centers for Disease Control and Prevention (CDC) safety protocols and recommendations and will comply with all federal, state, and local regulations in force at the time of the event.
CE Credit applications for physicians, pharmacists, and technologists (AMA PRA, VOICE, and ACPE credits) are pending. Check back for updates regarding CE Credit status.
This event is supported through a medical education grant from Novartis Pharmaceuticals Corporation.